Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.38 |
| ▸ | RELA | Q04206 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852586 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL968867 | 1.00 | NFKB1 (0.38) | NFKB1NFKB2RELA | |
| SCHEMBL2953173 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL4417335 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL5613785 | 0.83 | NFKB1 (0.30) | NFKB1NFKB2RELA | |
| SCHEMBL3449840 | 0.81 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL5634238 | 0.81 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL13734264 | 0.76 | NLRP3 (0.39) | NFKB1NFKB2RELA | |
| SCHEMBL15007568 | 0.75 | — | — | |
| SCHEMBL8577970 | 0.73 | NFKB1 (0.46) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | claimed |
| EP-3663305-B1 | METHOD FOR INTRODUCING SUBSTITUENTS INTO ALPHA,BETA-UNSATURATED KETONE AND PROSTAGLANDIN COMPOUND SYNTHESIS METHOD UTILIZING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2023-08-30 | — | — | EP | disclosed |
| CN-110959009-B | Method for introducing substituent to alpha, beta-unsaturated ketone and method for synthesizing prostanoid using the same | 国立研究开发法人国立长寿医疗研究中心 | 2023-02-28 | — | — | CN | disclosed |
| US-11384044-B2 | Method for introducing substituent into α,β-unsaturated ketone and method for synthesizing prostaglandin using the same | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20210355061-A1 | METHOD FOR INTRODUCING SUBSTITUENT INTO alpha,beta-UNSATURATED KETONE AND METHOD FOR SYNTHESIZING PROSTAGLANDIN USING THE SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2021-11-18 | — | — | US | disclosed |
| EP-3663305-A1 | METHOD FOR INTRODUCING SUBSTITUENTS INTO , -UNSATURATED KETONE AND PROSTAGLANDIN COMPOUND SYNTHESIS METHOD UTILIZING SAME | National Center for Geriatrics and Gerontology (JP) | 2020-06-10 | — | — | EP | disclosed |
| CN-110959009-A | Method for introducing substituent to α -unsaturated ketone and method for synthesizing prostanoid using same | 国立研究开发法人国立长寿医疗研究中心 | 2020-04-03 | — | — | CN | disclosed |
| EP-1537066-B1 | CYCLOPENTENONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | BIOGEM S C AR L (IT) | 2017-01-25 | — | — | EP | disclosed |
| US-9394273-B2 | Therapeutic prostaglandin receptor agonists | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2015175984-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-0197800-A2 | 5-Thiaprostaglandins E1 and process for producing same | TEIJIN LIMITED (JP) | 1986-10-15 | — | — | EP | disclosed |
| EP-0178139-A2 | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof | TEIJIN LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0173753-A1 | 6-SUBSTITUTED PROSTAGLANDIN E1'S AND PROCESS FOR THEIR PREPARATION | TEIJIN LIMITED (JP) | 1986-03-12 | — | — | EP | disclosed |
| EP-0038613-B1 | NOVEL PROSTAGLANDINS E1 AND ANTI-THROMBOTIC COMPOSITIONS CONTAINING THEM | TEIJIN LIMITED (JP) | 1984-08-29 | — | — | EP | disclosed |
| EP-0102230-A2 | Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof | TEIJIN LIMITED (JP) | 1984-03-07 | — | — | EP | disclosed |
| US-4315032-A | ANTITHROMBOGENIC AGENTS, ANTIULCER AGENTS | TEITIN LIMITED (JP) | 1982-02-09 | — | — | US | disclosed |
| EP-0038613-A1 | Novel prostaglandins E1 and anti-thrombotic compositions containing them | TEIJIN LIMITED (JP) | 1981-10-28 | — | — | EP | disclosed |
| EP-0019475-A2 | Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them | TEIJIN LIMITED (JP) | 1980-11-26 | — | — | EP | disclosed |
| EP-0013620-A1 | Process for the peparation of 4-hydroxycyclopent-2-enone and derivatives | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1980-07-23 | — | — | EP | disclosed |
| US-4132726-A | INTERMEDIATES FOR PROSTAGLANDIN COMPOUNDS | TEIJIN LIMITED (JP) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355061-A1 | METHOD FOR INTRODUCING SUBSTITUENT INTO alpha,beta-UNSATURATED KETONE AND METHOD FOR SYNTHESIZING PROSTAGLANDIN USING THE SAME | PTGES, PTGES2, PTGES3 | NFKB1 577/4885NFKB2 992/4885RELA 611/4885 |
| US-11384044-B2 | Method for introducing substituent into α,β-unsaturated ketone and method for synthesizing prostaglandin using the same | PTGES, PTGES2, PTGES3 | NFKB1 518/4885NFKB2 899/4885RELA 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.